Spielmeyer–Vogt disease

Spielmeyer–Vogt disease
ICD-10
ICD-9
DiseasesDB
MedlinePlus
eMedicine
MeSH ID

Spielmeyer–Vogt disease, also known as juvenile neuronal ceroid lipofuscinosis (JNCL), is a rare, inherited neurodegenerative disorder that primarily affects children. It is one of the forms of neuronal ceroid lipofuscinosis (NCL), a group of disorders characterized by the accumulation of lipopigments in the body's tissues.

Etiology

Spielmeyer–Vogt disease is caused by mutations in the CLN3 gene, which is located on chromosome 16. This gene is responsible for producing a protein that is involved in the normal functioning of lysosomes, the cellular organelles that break down waste materials and cellular debris. Mutations in the CLN3 gene lead to the accumulation of lipofuscins, which are fatty substances, in the brain and other tissues.

Clinical Presentation

The disease typically presents in childhood, usually between the ages of 4 and 10. The initial symptoms often include progressive vision loss due to retinal degeneration, which can lead to blindness. Other symptoms include seizures, cognitive decline, motor disturbances, and behavioral changes. As the disease progresses, affected individuals may experience loss of speech, dementia, and motor skills deterioration.

Diagnosis

Diagnosis of Spielmeyer–Vogt disease is based on clinical evaluation, family history, and genetic testing to identify mutations in the CLN3 gene. Additional diagnostic tools may include electroretinography to assess retinal function, magnetic resonance imaging (MRI) to detect brain changes, and electron microscopy to identify characteristic storage material in tissues.

Management

There is currently no cure for Spielmeyer–Vogt disease. Treatment is primarily supportive and focuses on managing symptoms. This may include anticonvulsant medications to control seizures, physical therapy to maintain mobility, and educational support for cognitive and behavioral issues. Research is ongoing to find more effective treatments, including gene therapy and enzyme replacement therapy.

Prognosis

The prognosis for individuals with Spielmeyer–Vogt disease is poor. The disease is progressive, and most affected individuals lose their ability to walk and communicate by their late teens or early twenties. Life expectancy is significantly reduced, with many individuals not surviving beyond their third decade of life.

Also see

• Neuronal ceroid lipofuscinosis
• Batten disease
• Lysosomal storage disease
• Genetic disorders